Publication Name	World Journal of Hepatology
Manuscript ID	104056
Country	Australia

Received	2024-12-09 04:46
Peer-Review Started	2024-12-09 04:46
To Make the First Decision
Return for Revision	2025-02-09 03:03
Revised	2025-02-21 11:13
Second Decision	2025-04-03 02:38
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-04-03 07:41
Articles in Press	2025-04-03 07:41
Publication Fee Transferred	2025-03-06 21:50
Edit the Manuscript by Language Editor
Typeset the Manuscript	2025-04-15 07:30
Publish the Manuscript Online	2025-04-25 08:23

ISSN	1948-5182 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Retrospective Cohort Study
Article Title	Rifaximin-α use is associated with improved muscle mass in patients with cirrhosis
Manuscript Source	Unsolicited Manuscript
All Author List	Thomas Worland, Penelope Hey, Darren Wong, Ross Apostolov, Roseanne Kimberley Chan, Marie Sinclair and Paul Gow
ORCID	Author(s) ORCID Number Thomas Worland http://orcid.org/0000-0001-5122-5750 Penelope Hey http://orcid.org/0000-0002-5219-0382 Darren Wong http://orcid.org/0000-0003-1490-0547 Paul Gow http://orcid.org/0000-0001-6505-7233
Funding Agency and Grant Number	Funding Agency Grant Number Norgine, the marketing authorization holder of rifaximin-α (Xifaxan©)
Corresponding Author	Thomas Worland, MD, Gastroenterology, Monash Health, Clayton road, Clayton 3168, Victoria, Australia. tfworland@gmail.com
Key Words	Rifaximin; Encephalopathy; Cirrhosis; Liver transplantation; Sarcopaeni
Core Tip	Sarcopaenia is associated with poorer outcomes in cirrhotic patients. In our study Rifaximin use was found to be independently associated with improvement of muscle mass in patients with cirrhosis. Rifaximin's potential as a therapeutic agent directed against cirrhosis associated sarcopaenia will require prospective research.
Publish Date	2025-04-25 08:23
Citation	<p>Worland T, Hey P, Wong D, Apostolov R, Chan RK, Sinclair M, Gow P. Rifaximin-α use is associated with improved muscle mass in patients with cirrhosis. <i>World J Hepatol</i> 2025; 17(4): 104056</p>
URL	https://www.wjgnet.com/1948-5182/full/v17/i4/104056.htm
DOI	https://dx.doi.org/10.4254/wjh.v17.i4.104056

Full Article (PDF)	WJH-17-104056-with-cover.pdf
STROBE Statement	104056-STROBE-statement.pdf
Manuscript File	104056_Auto_Edited_035905.docx
Answering Reviewers	104056-answering-reviewers.pdf
Audio Core Tip	104056-audio.mp3
Biostatistics Review Certificate	104056-biostatistics-statement.pdf
Conflict-of-Interest Disclosure Form	104056-conflict-of-interest-statement.pdf
Copyright License Agreement	104056-copyright-assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	104056-foundation-statement.pdf
Signed Informed Consent Form(s) or Document(s)	104056-informed-consent-statement.pdf
Institutional Review Board Approval Form or Document	104056-institutional-review-board-statement.pdf
Peer-review Report	104056-peer-reviews.pdf
Scientific Misconduct Check	104056-scientific-misconduct-check.png
Scientific Editor Work List	104056-scientific-editor-work-list.pdf
CrossCheck Report	104056-crosscheck-report.pdf